Gland Pharma Gains as Fosun Cuts Stake

Fosun said the proceeds will help fund R&D, share repurchases and debt repayment. That matters because the group has spent the past two years deleveraging and has now opted to monetize part of an asset it has held since taking control of Gland in 2016, rather than pursuing a full exit after earlier valuation disputes and geopolitical sensitivities around Chinese ownership in India.

For Gland investors, the key point is that operating momentum has not slowed. The company recently named Deepak Sapra CEO-designate and cleared a USFDA inspection at its Visakhapatnam sterile oncology plant with no Form 483 observations, a regulatory outcome that supports the company’s push in complex injectables.

Brokerages remain constructive despite a sharp rally in the stock. ICICI Securities kept a “Buy” rating and a Rs 3,150 target, citing growth in the US and Europe, a healthy injectable pipeline, CDMO wins and management’s upgraded outlook. Elara Capital turned more cautious on valuation after the shares rose about 40% in three months, but said the growth trend remains intact.

That optimism is being backed by numbers. Gland reported nearly 20% revenue growth in the June quarter, helped by US demand and expansion in contract development and manufacturing. It has also won new CDMO business, including in GLP-1 therapies, and recently signed a manufacturing agreement with a global pharma company that could eventually generate $90 million to $100 million in annual revenue.

The stock’s technical setup also reflects the run-up: Gland has traded well above its 200-day moving average and its relative strength index has been elevated at times, showing how much of the market already has improved fundamentals priced in. Sun Pharma, a domestic peer, has also weakened in recent sessions, underscoring that investors are rewarding company-specific execution rather than lifting the broader pharma pack.

The next test is whether Gland can convert fresh contracts into sustained margin and revenue growth fast enough to justify higher multiples. Further updates on US demand, CDMO execution and any additional Fosun stake sales will likely keep the stock in focus.